Current Insight into the Regulation of PD-L1 in Cancer

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2022 Jul 30

PMID 35907881

Authors

Zhuandi Liu

Xibao Yu

Ling Xu

Yangqiu Li

Chengwu Zeng

Affiliations

Soon will be listed here.

Abstract

The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint. Studying the PD-L1 regulatory pattern of tumor cells will help elucidate the molecular mechanisms of tumor immune evasion and improve cancer treatment. Recent studies have found that tumor cells regulate PD-L1 at the transcriptional, post-transcriptional, and post-translational levels and influence the anti-tumor immune response by regulating PD-L1. In this review, we focus on the regulation of PD-L1 in cancer cells and summarize the underlying mechanisms.

Citing Articles

Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis.

Chien Y, Wu J, Liu L, Yu Y Cell Death Discov. 2025; 11(1):85.

PMID: 40038276 PMC: 11880297. DOI: 10.1038/s41420-025-02368-1.

Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction.

Zhu Y, Zhang X, Jin J, Wang X, Liu Y, Gao J Exp Hematol Oncol. 2025; 14(1):16.

PMID: 39955603 PMC: 11829442. DOI: 10.1186/s40164-025-00611-0.

Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma.

Leshem R, Sefton K, Wong C, Lin I, Isaac D, Niepel M J Immunother Cancer. 2025; 13(1).

PMID: 39870492 PMC: 11772928. DOI: 10.1136/jitc-2024-010683.

Nuclear transmembrane protein 199 promotes immune escapes by up-regulating programmed death ligand 1.

You W, Luu H, Li M, Chen Z, Li F, Zhang Y iScience. 2025; 27(12):111485.

PMID: 39758995 PMC: 11699465. DOI: 10.1016/j.isci.2024.111485.

Calcium Channel Blocker Lacidipine Promotes Antitumor Immunity by Reprogramming Tryptophan Metabolism.

Sheng Y, Qiao C, Zhang Z, Shi X, Yang L, Xi R Adv Sci (Weinh). 2024; 12(3):e2409310.

PMID: 39585774 PMC: 11744582. DOI: 10.1002/advs.202409310.

References

Zhu L, Kuang X, Zhang G, Liang L, Liu D, Hu B . Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. J Immunother Cancer. 2022; 10(5). PMC: 9115032. DOI: 10.1136/jitc-2021-003819. View

Li Z, Suo B, Long G, Gao Y, Song J, Zhang M . Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer. Front Cell Dev Biol. 2020; 8:572689. PMC: 7734296. DOI: 10.3389/fcell.2020.572689. View

Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

Zhao L, Liu Y, Zhang J, Liu Y, Qi Q . LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019; 10(10):731. PMC: 6769008. DOI: 10.1038/s41419-019-1886-5. View

Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K . MA Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021; 81(18):4778-4793. DOI: 10.1158/0008-5472.CAN-21-0468. View

Amini M, Hejazi M, Ghorban K, Mokhtarzadeh A, Baradaran B . Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer. Gene. 2020; 772:145376. DOI: 10.1016/j.gene.2020.145376. View

Wang J, Jia Y, Zhao S, Zhang X, Wang X, Han X . BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene. 2017; 36(45):6235-6243. DOI: 10.1038/onc.2017.217. View

Dorand R, Nthale J, Myers J, Barkauskas D, Avril S, Chirieleison S . Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016; 353(6297):399-403. PMC: 5051664. DOI: 10.1126/science.aae0477. View

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

10.

Duan M, Fang M, Wang C, Wang H, Li M . LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis. Cancer Manag Res. 2020; 12:2141-2154. PMC: 7102881. DOI: 10.2147/CMAR.S229013. View

11.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

12.

Mohammadi P, Hesari M, Chalabi M, Salari F, Khademi F . An overview of immune checkpoint therapy in autoimmune diseases. Int Immunopharmacol. 2022; 107:108647. DOI: 10.1016/j.intimp.2022.108647. View

13.

Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y . Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021; 14(1):146. PMC: 8442312. DOI: 10.1186/s13045-021-01155-6. View

14.

Yamaguchi H, Hsu J, Yang W, Hung M . Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022; 19(5):287-305. DOI: 10.1038/s41571-022-00601-9. View

15.

Huang K, Chiang S, Chen W, Chen T, Hu C, Yang P . Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. Cancers (Basel). 2020; 12(2). PMC: 7072566. DOI: 10.3390/cancers12020462. View

16.

Gao Y, Nihira N, Bu X, Chu C, Zhang J, Kolodziejczyk A . Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020; 22(9):1064-1075. PMC: 7484128. DOI: 10.1038/s41556-020-0562-4. View

17.

Chen C, Liang C, Wang S, Chio C, Zhang Y, Zeng C . Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020; 13(1):28. PMC: 7118887. DOI: 10.1186/s13045-020-00853-x. View

18.

Angeloni A, Bogdanovic O . Enhancer DNA methylation: implications for gene regulation. Essays Biochem. 2019; 63(6):707-715. DOI: 10.1042/EBC20190030. View

19.

Lailler C, Lamuraglia M, Racine F, Louandre C, Godin C, Chauffert B . DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU). Transl Oncol. 2021; 14(8):101110. PMC: 8111315. DOI: 10.1016/j.tranon.2021.101110. View

20.

Faktor J, Pjechova M, Hernychova L, Vojtesek B . Protein Ubiquitination Research in Oncology. Klin Onkol. 2019; 32(Supplementum 3):56-64. DOI: 10.14735/amko20193S. View